Piper Sandler raises Arvinas stock price target to $16 on LRRK2 degrader data
PositiveFinancial Markets

Piper Sandler has raised its stock price target for Arvinas to $16, following promising data on the LRRK2 degrader. This adjustment reflects growing confidence in Arvinas' potential to innovate in the biotech sector, particularly in treatments for neurodegenerative diseases. Investors are likely to view this as a positive sign, indicating that the company's research is gaining traction and could lead to significant advancements in patient care.
— Curated by the World Pulse Now AI Editorial System